Transthyretin sequesters amyloid beta protein and prevents amyloid formation.
AUTOR(ES)
Schwarzman, A L
RESUMO
The cardinal pathological features of Alzheimer disease are depositions of aggregated amyloid beta protein (A beta) in the brain and cerebrovasculature. However, the A beta is found in a soluble form in cerebrospinal fluid in healthy individuals and patients with Alzheimer disease. We postulate that sequestration of A beta precludes amyloid formation. Failure to sequester A beta in Alzheimer disease may result in amyloidosis. When we added A beta to cerebrospinal fluid of patients and controls it was rapidly sequestered into stable complexes with transthyretin. Complexes with apolipoprotein E, which has been shown to bind A beta in vitro, were not observed in cerebrospinal fluid. Additional in vitro studies showed that both purified transthyretin and apolipoprotein E prevent amyloid formation.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=44607Documentos Relacionados
- Inhibiting transthyretin amyloid fibril formation via protein stabilization
- Alpha 1-antichymotrypsin regulates Alzheimer beta-amyloid peptide fibril formation.
- Tertiary structure of an amyloid immunoglobulin light chain protein: a proposed model for amyloid fibril formation.
- Inhibiting transthyretin conformational changes that lead to amyloid fibril formation
- Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation.
